
Sun Pharma Advanced Research Board Approves Unaudited Financial Results
Sun Pharma Advanced Research Company Ltd announced that its Board of Directors, in a meeting held on August 10, 2026, approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company also approved requests for reclassification of certain promoter group individuals to the 'Public' category, subject to necessary regulatory approvals. The board meeting commenced at 11:00 AM IST and concluded at 01:10 PM IST. A limited review report from the independent auditor is annexed with the financial results.
Key Highlights
- Board approved unaudited financial results for Q1 FY27.
- Results are for standalone and consolidated financial statements.
- Promoter group reclassification requests were approved.
- Reclassification is subject to regulatory approvals.
- Limited Review Report from auditors is attached.
Price Impact
More from SPARC
Sun Pharma Advanced Research Co. gets stock exchange nod for promoter reclassification
Sun Pharma Advanced Research Confirms Regulatory Compliance
Sun Pharma Advanced Research: Monitoring Agency Report Q3 2026